Kanion Pharmaceutical: Clinical trial for Jianpi Shugan Guben Granules approved

Zhitong
2025.08.18 09:19
portai
I'm PortAI, I can summarize articles.

According to the Zhitong Finance APP, Kanion Pharmaceutical announced that the company has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for the Jianpi Shugan Guben Granules. The relevant drug is Jianpi Shugan Guben Granules, indicated for diarrhea-type irritable bowel syndrome with liver stagnation and spleen deficiency

According to the Zhitong Finance APP, Kanion Pharmaceutical (600557.SH) announced that the company has received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration for the product Jianpi Shugan Guben Granules. The indication for this drug is diarrhea-type irritable bowel syndrome with liver stagnation and spleen deficiency

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer